Did you know that overall median survival for patients with brain metastases has improved according to more recent analyses compared with previous reports?(1)

This leads to new challenges for clinicians in deciding how to further treat a patient with new or recurring metastases.

That's where Brainlab Elements Retreatment Review software comes into play, supporting the complex follow-up and decision-making process for patients with multiple brain metastases as well as the re-treatment planning.

As stated by Professor Cordula Petersen, MD, Director of the Clinic for Radiotherapy and Radiation Oncology at the @Universitätsklinikum Hamburg Eppendorf, "the Retreatment Analysis tool from Brainlab helps us document all the repeated courses of radiosurgery of an individual patient: we can now match all these different treatments within one picture and add the new MRI to decide what type of radiosurgery we can offer the patient. This is a really a big advantage."

Have a look to the interview: Evolution of Multiple Brain Mets Retreatment Analysis -Interview (novaliscircle.org)

Watch the full talk by Prof. Petersen to learn more about our Elements Retreatment Workflow: https://www.novaliscircle.org/page/view-video?id=395

(1). Sperduto et al. Survival in patients with multiple brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. Journal of Clinical Oncology. 2020; 38 (32): 3773-3784

#oncology #brainmets #cancer #radiotherapy #medtech #digitalhealth